BIOCELTIX S.A. ZY -10 Total Assets
BIOCELTIX S.A. ZY -10 total assets. Based on the latest financial reports, BIOCELTIX S.A. ZY -10 (XI3) holds total assets worth €75.63 Million EUR (≈ $88.42 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see XI3 company net worth for the company's overall valuation and market capitalisation.
Total Assets of BIOCELTIX S.A. ZY -10 (2021–2025)
Total assets of BIOCELTIX S.A. ZY -10 from 2021 to 2025. This chart illustrates how BIOCELTIX S.A. ZY -10's total assets have evolved over time, based on quarterly financial data. See XI3 stock price and chart for real-time trading data and today's change.
BIOCELTIX S.A. ZY -10 - Asset Composition Analysis
BIOCELTIX S.A. ZY -10 Total Assets Breakdown (December 2025)
BIOCELTIX S.A. ZY -10 total assets breakdown as of December 2025. BIOCELTIX S.A. ZY -10's total assets of €75.63 Million consist of 94.3% current assets and 5.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 90.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how BIOCELTIX S.A. ZY -10's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore XI3 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BIOCELTIX S.A. ZY -10's current assets represent 94.3% of total assets in 2025, an increase from 79.4% in 2021.
- Cash Position: Cash and equivalents constituted 90.4% of total assets in 2025, up from 73.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
BIOCELTIX S.A. ZY -10 Competitors by Total Assets
Key competitors of BIOCELTIX S.A. ZY -10 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
BIOCELTIX S.A. ZY -10 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 32.51 | 18.69 | 15.50 |
| Quick Ratio | 32.51 | 18.68 | 15.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €69.10 Million | €36.59 Million | €38.99 Million |
BIOCELTIX S.A. ZY -10 - Advanced Valuation Insights
This section examines the relationship between BIOCELTIX S.A. ZY -10's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.36 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 80.7% |
| Total Assets | €75.63 Million |
| Market Capitalization | $89.73 Million USD |
Valuation Analysis
Above Book Valuation: The market values BIOCELTIX S.A. ZY -10's assets above their book value (1.19x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: BIOCELTIX S.A. ZY -10's assets grew by 80.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BIOCELTIX S.A. ZY -10 (2021–2025)
The table below shows the annual total assets of BIOCELTIX S.A. ZY -10 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €75.63 Million ≈ $88.42 Million |
+80.70% |
| 2024-12-31 | €41.85 Million ≈ $48.93 Million |
+228.65% |
| 2023-12-31 | €12.74 Million ≈ $14.89 Million |
+66.40% |
| 2022-12-31 | €7.65 Million ≈ $8.95 Million |
-6.62% |
| 2021-12-31 | €8.20 Million ≈ $9.58 Million |
-- |
About BIOCELTIX S.A. ZY -10
Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company's products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug candidate based on allogeneic stem cells for the treatment of atopic dermatitis in dogs; and BCX-EM, a drug candidate based on allogeneic mesenchymal stem cells … Read more